STL001

Overview

STL001 is potent and selective FOXM1 inhibitor. STL001 induces the translocation of nuclear FOXM1 to the cytoplasm and promotes its autophagic degradation. STL001 sensitizes human cancers to a broad-spectrum of cancer therapies.

Application

Products | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Chronic Lymphocytic Leukemia | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FOXM1 | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-158420
• CAS No.: 3047493-70-6
• Molecular Formula: C27H23N7O4
• Molecular Weight: 509.52
• Purity: 99.81%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source